VE707 is a preclinical discovery program for the prevention of infection and colonization recurrence of several multi-drug resistant organisms (MDROs) including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE), which are some of the most common hospital-acquired infections. VE707 is designed to be administered orally and consists of a rationally-designed bacterial consortium that decolonizes gut-dwelling MDROs in patients at high risk for developing infections. It is produced from pure, clonal bacterial cell banks, which yield a product of uniform composition and free of any pathogenic strains, bypassing the need to rely on fecal donor material with inconsistent composition.

In December 2019, Vedanta announced that it was awarded a $5.8 million grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its VE707 program. In April 2024, Vedanta announced a $3.9 million award from CARB-X to ready VE707 for a first-in-human study for the prevention of multidrug-resistant (MDR) infections.